PureTech Health (LON:PRTC) Stock Passes Below Fifty Day Moving Average - Here's Why

Key Points

• PureTech Health's share price has fallen below its 50-day moving average of GBX 129.64 ($1.76), closing at GBX 106.40 ($1.44) with a trading volume of over 3 million shares.
• The company has a current market capitalization of £269.72 million and a notably high P/E ratio of 656.47.
• Insider Bharatt Chowrira purchased 167,739 shares of the company at GBX 1 per share, indicating confidence in the company's future.

PureTech Health plc (LON:PRTC - Get Free Report) shares passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of GBX 129.64 ($1.75) and traded as low as GBX 104.71 ($1.42). PureTech Health shares last traded at GBX 106.40 ($1.44), with a volume of 3,343,608 shares traded.

PureTech Health Stock Performance

The stock has a market cap of £303.07 million, a price-to-earnings ratio of 737.65 and a beta of 1.02. The company has a debt-to-equity ratio of 45.82, a quick ratio of 2.51 and a current ratio of 3.68. The stock's 50-day simple moving average is GBX 129.31 and its two-hundred day simple moving average is GBX 129.65.

Insider Buying and Selling at PureTech Health

In other PureTech Health news, insider Bharatt Chowrira bought 167,739 shares of the firm's stock in a transaction that occurred on Thursday, July 3rd. The stock was purchased at an average price of GBX 1 per share, for a total transaction of £1,677.39. Corporate insiders own 13.13% of the company's stock.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.